Abstract
A self-microemulsifying drug delivery system (SMEDDS) of Brucea javanica oil (BJO) was developed and evaluated for its oral absorption and bioavailability. Based on a solubility study and pseudo-ternary phase diagrams, the self-microemulsifying formulation composed of BJO, Cremorphor RH40, Plurol Oleique CC 497 and glycerol (30/42/20/8, % w/w) was prepared and characterised, including particle size, morphology, in vitro cytotoxicity and in vivo anti-tumour effects. The mean diameter of the final formulation was 41.5±3.5 nm. The BJO-loaded SMEDDS (BJOS) and the control preparation of BJO were administered orally to beagle dogs for pharmacokinetics and bioavailability studies. Oleic acid, which was considered as the main active and indicative component in BJO, was determined by gas chromatography. The cytotoxicity and anti-tumour effects of BJOS were evaluated in SMMC-7721 and BGC-823 cancer cell lines and sarcoma 180-bearing mice. The data showed that the oral relative bioavailability of commercial emulsion of BJO (BJOE) was 2.3-fold higher than that of BJO. Moreover, the IC50 value of BJOS group was nearly one-fourth compared to that of commercial BJOE. BJOS could significantly inhibit tumour growth via intra-gastric administration. The Letter illustrates that the developed SMEDDS formulation possessed great potential to be an alternative for traditional oral formulations of BJO.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
